. Author manuscript; available in PMC: 2014 Jul 15.

Published in final edited form as: Int J Cardiol. 2012 Jan 17;167(1):151–156. doi: 10.1016/j.ijcard.2011.12.056

Table 5.

Change in systolic blood pressure, serum potassium and creatinine values during first 12 months of follow-up, in patients in the placebo and enalapril groups in the SOLVD-Treatment trial

		Changes during first 12 months Mean (95% CI); paired t-test p value	Student’s t-test p value

Systolic blood pressure, mm Hg
CKD (n=983)	Placebo (n=508)	+0.10 (−1.21 to +1.41); 0.880	<0.001
CKD (n=983)	Enalapril (n=475)	−7.00 (−8.62 to −5.38); <0.001^*	<0.001
No CKD (n=1411)	Placebo (n=677)	+0.60 (−0.53 to +1.72); 0.297	<0.001
No CKD (n=1411)	Enalapril (n=734)	−7.06 (−8.23 to −5.90); <0.001^*	<0.001
Serum potassium, mEq/L
CKD (n=970)	Placebo (n=503)	−0.06 (−0.11 to −0.02); 0.008	<0.001
CKD (n=970)	Enalapril (n=467)	+0.20 (+0.14 to +0.25); <0.001^†	<0.001
No CKD (n=1384)	Placebo (n=670)	−0.04 (−0.08 to +0.003); 0.069	<0.001
No CKD (n=1384)	Enalapril (n=714)	+0.18 (+0.14 to +0.22); <0.001^†	<0.001
Serum creatinine, mg/dL
CKD (n=967)	Placebo (n=501)	−0.02 (−0.05 to −0.001); 0.041	<0.001
CKD (n=967)	Enalapril (n=466)	+0.04 (+0.02 to +0.07); 0.002^‡	<0.001
No CKD (n=1383)	Placebo (n=670)	+0.05 (+0.03 to +0.06); <0.001	<0.001
No CKD (n=1383)	Enalapril (n=713)	+0.09 (+0.08 to +0.11); <0.001^‡	<0.001

P=0.948 for differences in patients in the enalapril group with and without CKD

^†

P=0.632 for differences in patients in the enalapril group with and without CKD

^‡

P=0.003 for differences in patients in the enalapril group with and without CKD